Exploring Angiotensin II Receptor Blockers as a potential protective therapeutic for the Preclinical Stages of Alzheimer's Disease

Abstract

Background: There has been a growing interest in providing pharmacological therapy for the stage in Alzheimer's Disease (AD) where there are no noticeable cognitive symptoms, but pathological changes begin. This stage is defined as Preclinical AD.